Parnell Pharmaceuticals Holdings Ltd Announces Fiscal Year 2014 Financial Results
September 15, 2014 16:00 ET
|
Parnell Pharmaceuticals Holdings Ltd
OVERLAND PARK, Kan., Sept. 15, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...
Parnell to Report Fiscal Year 2014 Financial Results September 15, 2014
September 10, 2014 15:40 ET
|
Parnell Pharmaceuticals Holdings Ltd
OVERLAND PARK, Kan., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...
Parnell Appoints US-Based Independent Directors Phyllis Gardner, M.D., and David L. Greenwood to Its Board of Directors
September 08, 2014 17:31 ET
|
Parnell Pharmaceuticals Holdings Ltd
OVERLAND PARK, Kan., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN) today announced that it had appointed U.S. based Phyllis Gardner, MD, and David L. Greenwood...
Parnell Announces Results From the Successful Efficacy Study for Zydax(R)
September 03, 2014 18:06 ET
|
Parnell Pharmaceuticals Holdings Ltd
OVERLAND PARK, Kan., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN) today announced the results from a successful, large-scale efficacy study of Zydax, for the...